Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
| 3.93 | |
| 4.02 | |
| - | |
| 4.06 | |
| 3.91 | |
| 2.415-7.2225 | |
| 121 M | |
| 30 174 K | |
| 0 | |
| -0.72 | |
| 0.497 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Key Insights Relmada Therapeutics' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the ...
Longboard Pharmaceuticals, Walgreens Boots Alliance and more in the latest Market Talks covering the Health Care sector. Continue reading
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
